Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Cornberg

Showing results (311-320 of 350) with videos related to

Pageof 35
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|October 1, 2017
Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN)Anika Wranke, Lourdes M Pinheiro Borzacov, Raymundo Parana, et al.
The New England Journal of Medicine|June 22, 2023
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis DHeiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, et al.
Journal of Hepatology|April 12, 2026
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trialHeiner Wedemeyer, Soo Aleman, Antje Blank, et al.
Frontiers in Immunology|November 28, 2022
Immune escape pathways from the HBV core<sub>18-27</sub> CD8 T cell response are driven by individual HLA class I allelesAndreas Walker, Tatjana Schwarz, Janine Brinkmann-Paulukat, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 3, 2023
Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis DOlympia E Anastasiou, Florin A Caruntu, Manuela G Curescu, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 14, 2026
S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - part 1: Treatment recommendations and monitoringAlexander Nast, Andreas Altenburg, Matthias Augustin, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 5, 2026
S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 2: Specific clinical and comorbid situationsAlexander Nast, Andreas Altenburg, Matthias Augustin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2020
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J Sonneveld, Jun Yong Park, Apichat Kaewdech, et al.
Journal of Hepatology|May 11, 2024
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trialHeiner Wedemeyer, Soo Aleman, Maurizia Brunetto, et al.
Immunity|February 10, 2021
COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responsesAgnes Bonifacius, Sabine Tischer-Zimmermann, Anna C Dragon, et al.
Pageof 35

Showing results (311-320 of 350) with videos related to

Sort By:
Pageof 35
Liver International : Official Journal of the International Association for the Study of the Liver|October 1, 2017
Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN)Anika Wranke, Lourdes M Pinheiro Borzacov, Raymundo Parana, et al.
The New England Journal of Medicine|June 22, 2023
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis DHeiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, et al.
Journal of Hepatology|April 12, 2026
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trialHeiner Wedemeyer, Soo Aleman, Antje Blank, et al.
Frontiers in Immunology|November 28, 2022
Immune escape pathways from the HBV core<sub>18-27</sub> CD8 T cell response are driven by individual HLA class I allelesAndreas Walker, Tatjana Schwarz, Janine Brinkmann-Paulukat, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 3, 2023
Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis DOlympia E Anastasiou, Florin A Caruntu, Manuela G Curescu, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 14, 2026
S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - part 1: Treatment recommendations and monitoringAlexander Nast, Andreas Altenburg, Matthias Augustin, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 5, 2026
S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 2: Specific clinical and comorbid situationsAlexander Nast, Andreas Altenburg, Matthias Augustin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2020
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J Sonneveld, Jun Yong Park, Apichat Kaewdech, et al.
Journal of Hepatology|May 11, 2024
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trialHeiner Wedemeyer, Soo Aleman, Maurizia Brunetto, et al.
Immunity|February 10, 2021
COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responsesAgnes Bonifacius, Sabine Tischer-Zimmermann, Anna C Dragon, et al.
Pageof 35